Pathophysiology of Intracerebral Hemorrhage: Recovery Trajectories
- PMID: 39676669
- DOI: 10.1161/STROKEAHA.124.046130
Pathophysiology of Intracerebral Hemorrhage: Recovery Trajectories
Abstract
Recovery trajectories in intracerebral hemorrhage (ICH) are recognized as distinct from those observed in ischemic stroke. This narrative review aims to clarify the pathophysiology underlying ICH recovery patterns, highlighting the unique timeline and nature of functional improvements seen in ICH survivors. Population-based cohort studies tracking functional outcomes in a longitudinal fashion, along with randomized clinical trial data with standardized outcome assessments, have demonstrated that ICH recovery generally has a delayed onset in the first weeks, followed by a steep early subacute stage recovery (typically up to 3 months) continuing in protracted, gradual improvements beyond 3 to 6 months. Understanding these recovery patterns, and how these differ from ischemic stroke, is crucial for providing accurate prognostic information, facilitating targeted health care delivery, and optimizing therapeutic interventions and the design of ICH randomized trials. This article synthesizes current evidence on early- and late-stage functional recovery trajectories in primary, spontaneous ICH and cognitive outcomes, emphasizing the clinical and research implications of these recovery patterns.
Keywords: cerebral hemorrhage; cognition; cohort studies; outcome assessment, health care; physiology; prognosis; recovery of function.
Conflict of interest statement
Dr Katsanos reports grants from the Heart and Stroke Foundation of Canada; compensation from Diamedica, Inc, for consultant services; and employment by McMaster University. Dr Selim reports grants from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke; other intellectual property for authoring a section on secondary prevention of intracerebral hemorrhage; compensation from Alnylam Pharmaceuticals for data and safety monitoring services; compensation from Valin Technologies for consultant services; grants from NIH/National Institute on Aging; stock holdings in NeuGel, Inc; compensation from MedRhythms, Inc, for consultant services; and employment by Beth Israel Deaconess Medical Center. Dr Shoamanesh reports grants from Daiichi Sankyo Company; compensation from Daiichi Sankyo Company for consultant services; compensation from AstraZeneca for consultant services; compensation from Bayer for data and safety monitoring services; grants from Canadian Institutes of Health Research; grants from Servier Affaires Medicales; grants from the NIH; grants from Octapharma USA, Inc; grants from Bayer; grants from Canadian Institutes of Health Research; compensation from Takeda Pharmaceutical Company for consultant services; grants from Bayer; grants from Heart and Stroke Foundation of Canada; compensation from Bayer for consultant services; and grants from AstraZeneca. The other authors report no conflicts.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources